Alexander T Cohen

List of Publications by Year
in descending order

171	22,233	53794 45	8396 147
papers	citations	h-index	g-index

173	173	173	11501
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New England Journal of Medicine, 2010, 363, 2499-2510.	27.0	2,807
2	Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. New England Journal of Medicine, 2012, 366, 1287-1297.	27.0	2,080
3	Oral Apixaban for the Treatment of Acute Venous Thromboembolism. New England Journal of Medicine, 2013, 369, 799-808.	27.0	1,915
4	Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet, The, 2008, 371, 387-394.	13.7	1,258
5	Apixaban for Extended Treatment of Venous Thromboembolism. New England Journal of Medicine, 2013, 368, 699-708.	27.0	1,116
6	Venous thromboembolism (VTE) in Europe. Thrombosis and Haemostasis, 2007, 98, 756-764.	3.4	1,100
7	Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients. Circulation, 2004, 110, 874-879.	1.6	856
8	Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ: British Medical Journal, 2006, 332, 325-329.	2.3	723
9	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine, 2016, 375, 1131-1141.	27.0	692
10	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine, 2019, 380, 1326-1335.	27.0	687
11	Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. New England Journal of Medicine, 2020, 382, 1599-1607.	27.0	658
12	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. New England Journal of Medicine, 2017, 376, 1211-1222.	27.0	577
13	Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thrombosis and Haemostasis, 2007, 98, 756-64.	3.4	531
14	Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. New England Journal of Medicine, 2013, 368, 513-523.	27.0	524
15	Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal, 2013, 11, 21.	2.1	471
16	Risk Factors for Venous Thromboembolism in Hospitalized Patients With Acute Medical Illness. Archives of Internal Medicine, 2004, 164, 963.	3.8	395
17	Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. New England Journal of Medicine, 2016, 375, 534-544.	27.0	379
18	Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thrombosis and Haemostasis, 2017, 117, 219-230.	3.4	337

#	Article	IF	Citations
19	A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einsteinâ€“DVT Dose-Ranging Study. Blood, 2008, 112, 2242-2247.	1.4	316
20	Estimated annual numbers of US acuteâ€care hospital patients at risk for venous thromboembolism. American Journal of Hematology, 2007, 82, 777-782.	4.1	257
21	Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology,the, 2014, 1, e37-e46.	4.6	244
22	Prevention of venous thromboembolism in medical patients with enoxaparin. Blood Coagulation and Fibrinolysis, 2003, 14, 341-346.	1.0	224
23	Estimated Annual Number of Incident and Recurrent, Non-Fatal and Fatal Venous Thromboembolism (VTE) Events in the US.. Blood, 2005, 106, 910-910.	1.4	224
24	Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. Thrombosis and Haemostasis, 2017, 117, 57-65.	3.4	193
25	Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thrombosis and Haemostasis, 2005, 94, 750-9.	3.4	173
26	Epidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer. Thrombosis and Haemostasis, 2014, 112, 255-263.	3.4	156
27	Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thrombosis and Haemostasis, 2005, 93, 76-79.	3.4	151
28	Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. Thrombosis and Haemostasis, 2018, 118, 1668-1678.	3.4	121
29	Efficacy and Safety of Fixed Low-Dose Dalteparin in Preventing Venous Thromboembolism Among Obese or Elderly Hospitalized Patients. Archives of Internal Medicine, 2005, 165, 341.	3.8	101
30	Why do we need observational studies of everyday patients in the real-life setting?: TableÂ1. European Heart Journal Supplements, 2015, 17, D2-D8.	0.1	101
31	The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. TH Open, 2017, 01, e56-e65.	1.4	94
32	Venous Thromboembolism Risk and Prophylaxis in the Acute Care Hospital Setting (ENDORSE Survey). Annals of Surgery, 2010, 251, 330-338.	4.2	93
33	Predicting atrial fibrillation in primary care using machine learning. PLoS ONE, 2019, 14, e0224582.	2.5	88
34	Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. Thrombosis and Haemostasis, 2010, 103, 736-748.	3.4	86
35	The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. American Heart Journal, 2014, 167, 335-341.	2.7	81
36	Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.8	76

#	Article	IF	Citations
37	The management of acute venous thromboembolism in clinical practice. Thrombosis and Haemostasis, 2017, 117, 1326-1337.	3.4	74
38	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Advances, 2018, 2, 788-796.	5.2	71
39	Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients. Circulation, 2017, 135, 648-655.	1.6	61
40	Treatment of venous thromboembolism with rivaroxaban in relation to body weight. Thrombosis and Haemostasis, 2016, 116, 739-746.	3.4	58
41	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology,the, 2016, 3, e228-e236.	4.6	55
42	Predicting the Risk of Venous Thromboembolism in Patients Hospitalized With Heart Failure. Circulation, 2014, 130, 410-418.	1.6	53
43	Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. American Journal of Hematology, 2019, 94, 21-28.	4.1	50
44	SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. Thrombosis and Haemostasis, 2021, 121, 982-991.	3.4	50
45	Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Thrombosis and Haemostasis, 2015, 114, 645-650.	3.4	48
46	The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Journal, 2017, 185, 93-100.	2.7	48
47	Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. Thrombosis and Haemostasis, 2018, 118, 2046-2052.	3.4	48
48	Thromboprophylaxis with dalteparin in medical patients: which patients benefit?. Vascular Medicine, 2007, 12, 123-127.	1.5	47
49	Managing pulmonary embolism from presentation to extended treatment. Thrombosis Research, 2014, 133, 139-148.	1.7	41
50	The management of acute venous thromboembolism in clinical practice â€“ study rationale and protocol of the European PREFER in VTE Registry. Thrombosis Journal, 2015, 13, 41.	2.1	40
51	Comparison of Fatal or Irreversible Events With Extendedâ€Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. Journal of the American Heart Association, 2017, 6, .	3.7	40
52	The Changing Pattern of Venous Thromboembolic Disease. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 65-71.	0.3	39
53	Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries. Quality of Life Research, 2019, 28, 2111-2124.	3.1	38
54	Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006â€“2015. European Heart Journal, 2020, 41, 1636-1649.	2.2	36

#	Article	IF	Citations
55	Correlation of Plasma Coagulation Parameters With Thromboprophylaxis, Patient Characteristics, and Outcome in the MEDENOX Study. Archives of Pathology and Laboratory Medicine, 2004, 128, 519-526.	2.5	36
56	Direct Oral Anticoagulant Concentrations in Obese and High Body Weight Patients: A Cohort Study. Thrombosis and Haemostasis, 2021, 121, 224-233.	3.4	35
57	Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice. Thrombosis and Haemostasis, 2018, 118, 1951-1961.	3.4	34
58	Phase III Trials of New Oral Anticoagulants in the Acute Treatment and Secondary Prevention of VTE: Comparison and Critique of Study Methodology and Results. Advances in Therapy, 2014, 31, 473-493.	2.9	32
59	Asia-Pacific Thrombosis Advisory Board consensus paper on prevention of venous thromboembolism after major orthopaedic surgery. Thrombosis and Haemostasis, 2010, 104, 919-930.	3.4	30
60	Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients. Journal of the American Heart Association, 2021, 10, e019459.	3.7	30
61	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology,the, 2016, 3, e437-e445.	4.6	29
62	Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. American Journal of Medicine, 2018, 131, 972.e1-972.e7.	1.5	29
63	Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. Thrombosis Research, 2018, 170, 181-191.	1.7	29
64	Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. New England Journal of Medicine, 2013, 368, 1944-1946.	27.0	28
65	Prevention of VTE in women with cancer. Thrombosis Research, 2011, 127, S5-S8.	1.7	27
66	The Efficacy and Safety of Pharmacological Prophylaxis of Venous Thromboembolism Following Elective Knee or Hip Replacement. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 611-627.	1.7	27
67	Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deepâ€Vein Thrombosis as Firstâ€Line Therapy (AMPLIFY) Trial. Journal of the American Heart Association, 2015, 4, .	3.7	27
68	Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients. Circulation, 2018, 137, 91-94.	1.6	27
69	The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. Thrombosis and Haemostasis, 2012, 107, 1035-1043.	3.4	25
70	Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis. Thrombosis and Haemostasis, 2021, 121, 383-395.	3.4	25
71	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. Thrombosis and Haemostasis, 2022, 122, 646-656.	3.4	25
72	Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE. Chest, 2016, 150, 1059-1068.	0.8	24

#	Article	IF	Citations
73	Prophylaxis of venous thromboembolism in medical patients. Current Opinion in Pulmonary Medicine, 2001, 7, 332-337.	2.6	23
74	How I manage venous thromboembolism risk in hospitalized medical patients. Blood, 2012, 120, 1562-1569.	1.4	23
75	Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. Thrombosis and Haemostasis, 2017, 117, 2389-2395.	3.4	22
76	Improving Practices in US Hospitals to Prevent Venous Thromboembolism: Lessons from ENDORSE. American Journal of Medicine, 2010, 123, 1099-1106.e8.	1.5	21
77	Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity. Journal of Clinical Medicine, 2021, 10, 200.	2.4	21
78	Epidemiology of post-operative venous thromboembolismin asian countries. International Journal of Angiology, 2004, 13, 101-108.	0.6	20
79	VTE prophylaxis for the medical patient: where do we stand? â€“ A focus on cancer patients. Thrombosis Research, 2010, 125, S21-S29.	1.7	20
80	COSIMO â€“ patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study. Thrombosis Journal, 2018, 16, 21.	2.1	20
81	Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer. Thrombosis and Haemostasis, 2020, 120, 847-856.	3.4	20
82	Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. American Heart Journal, 2018, 198, 84-90.	2.7	19
83	Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY. Advances in Therapy, 2021, 38, 3003-3018.	2.9	19
84	Rivaroxaban and the EINSTEIN clinical trial programme. Blood Coagulation and Fibrinolysis, 2019, 30, 85-95.	1.0	18
85	Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. Journal of Thrombosis and Haemostasis, 2021, 19, 2751-2759.	3.8	18
86	Anticoagulant selection for patients with VTEâ€”Evidence from a systematic literature review of network meta-analyses. Pharmacological Research, 2019, 143, 166-177.	7.1	17
87	Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. Intensive Care Medicine, 2019, 45, 477-487.	8.2	17
88	Managing venous thromboembolism in Asia: Winds of change in the era of new oral anticoagulants. Thrombosis Research, 2012, 130, 291-301.	1.7	16
89	Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. Thrombosis and Haemostasis, 2016, 115, 809-816.	3.4	16
90	Prevention of venous thromboembolism in ambulatory patients with cancer. ESMO Open, 2020, 5, e000948.	4.5	16

#	Article	IF	Citations
91	Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease. Thrombosis and Haemostasis, 2022, 122, 926-938.	3.4	16
92	Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study. Thrombosis Journal, 2018, 16, 9.	2.1	15
93	Thromboprophylaxis in non-surgical cancer patients. Thrombosis Research, 2012, 129, S137-S145.	1.7	14
94	Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences. BMC Health Services Research, 2017, 17, 74.	2.2	14
95	When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials. American Heart Journal, 2017, 189, 1-8.	2.7	14
96	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. Thrombosis Research, 2017, 149, 29-37.	1.7	14
97	Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. Journal of Thrombosis and Thrombolysis, 2018, 45, 1-8.	2.1	14
98	Identification of undiagnosed atrial fibrillation patients using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI): Study protocol for a randomised controlled trial. Contemporary Clinical Trials, 2020, 99, 106191.	1.8	14
99	Discoveries in Thrombosis Care for Medical Patients. Seminars in Thrombosis and Hemostasis, 2002, 28, 013-018.	2.7	13
100	Long-term benefits of preventing venous thromboembolic events. Current Medical Research and Opinion, 2012, 28, 877-889.	1.9	13
101	Use of Prestudy Heparin Did Not Influence the Efficacy and Safety of Rivaroxaban in Patients Treated for Symptomatic Venous Thromboemâ€bolism in the EINSTEIN DVT and EINSTEIN PE Studies. Academic Emergency Medicine, 2015, 22, 142-149.	1.8	13
102	Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. Thrombosis and Haemostasis, 2016, 115, 161-168.	3.4	13
103	Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. Thrombosis and Haemostasis, 2020, 120, 924-936.	3.4	12
104	VTE primary prevention, including hospitalised medical and orthopaedic surgical patients. Thrombosis and Haemostasis, 2015, 113, 1216-1223.	3.4	11
105	N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. Journal of Thrombosis and Thrombolysis, 2017, 44, 457-465.	2.1	11
106	Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients. Thrombosis and Haemostasis, 2018, 118, 174-181.	3.4	11
107	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Thrombosis Research, 2018, 168, 121-129.	1.7	11
108	Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses. Blood Advances, 2020, 4, 432-439.	5.2	11

#	Article	IF	Citations
109	Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. European Journal of Cancer, 2022, 165, 136-145.	2.8	11
110	Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence?. Thrombosis and Haemostasis, 2009, 101, 422-427.	3.4	10
111	Venous thromboembolism prevention and treatment: expanding the rivaroxaban knowledge base with real-life data. European Heart Journal Supplements, 2015, 17, D32-D41.	0.1	10
112	The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry. Thrombosis Research, 2017, 157, 181-188.	1.7	10
113	Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States. Pharmacoeconomics, 2019, 37, 701-714.	3.3	10
114	Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE. European Journal of Internal Medicine, 2021, 88, 43-51.	2.2	10
115	Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism â€“ The COSIMO study. Thrombosis Research, 2021, 206, 1-4.	1.7	10
116	Thirtyâ€day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for lifeâ€threatening direct oral anticoagulantâ€related bleeding. Journal of the American College of Emergency Physicians Open, 2022, 3, e12655.	0.7	10
117	Recognition of biomarker identified high-risk patients in the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban study resulting in a protocol amendment. American Heart Journal, 2015, 169, 186-187.	2.7	9
118	Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 227-232.	2.0	9
119	The impact of co-morbidity on the disease burden of VTE. Journal of Thrombosis and Thrombolysis, 2018, 46, 507-515.	2.1	9
120	Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE. Thrombosis and Haemostasis, 2019, 119, 675-684.	3.4	9
121	Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis. Quality of Life Research, 2019, 28, 1155-1177.	3.1	9
122	Derivation and Validation of a Prediction Model for Venous Thromboembolism in Primary Care. Thrombosis and Haemostasis, 2020, 120, 692-701.	3.4	9
123	An Adaptive-Design Dose-Ranging Study of PD 0348292, a New Oral Factor Xa Inhibitor, for Thromboprophylaxis after Total Knee Replacement Surgery.. Blood, 2008, 112, 980-980.	1.4	9
124	Competing risk analysis in a large cardiovascular clinical trial: An <scp>APEX</scp> substudy. Pharmaceutical Statistics, 2017, 16, 445-450.	1.3	8
125	Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thrombosis and Haemostasis, 2017, 117, 2406-2414.	3.4	8
126	Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. TH Open, 2018, 02, e16-e24.	1.4	8

#	Article	IF	Citations
127	Extended thromboprophylaxis with betrixaban: a new standard for acute medically ill patients. European Heart Journal Supplements, 2018, 20, E1-E2.	0.1	8
128	Prediction of significant bleeding during vitamin K antagonist treatment for venous thromboembolism in outpatients. British Journal of Haematology, 2020, 189, 524-533.	2.5	8
129	Identification of undiagnosed atrial fibrillation using a machine learning risk-prediction algorithm and diagnostic testing (PULsE-AI) in primary care: a multi-centre randomized controlled trial in England. European Heart Journal Digital Health, 2022, 3, 195-204.	1.7	8
130	Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status. Advances in Therapy, 2021, 38, 5519-5533.	2.9	7
131	Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210829.	1.7	7
132	Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI) in primary care: cost-effectiveness of a screening strategy evaluated in a randomized controlled trial in England. Journal of Medical Economics, 2022, 25, 974-983.	2.1	7
133	The utility of thromboelastography and thrombin generation in assessing the prothrombotic state of adults with sickle cell disease. Thrombosis Research, 2017, 158, 113-120.	1.7	6
134	Primary thromboembolic prevention in multiple myeloma patients: An exploratory meta-analysis on aspirin use. Seminars in Hematology, 2018, 55, 182-184.	3.4	6
135	Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. Journal of Thrombosis and Thrombolysis, 2020, 49, 214-219.	2.1	6
136	Impact of Thromboprophylaxis across the US Acute Care Setting. PLoS ONE, 2015, 10, e0121429.	2.5	6
137	Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation, 2022, 145, 1471-1479.	1.6	6
138	Treating pulmonary embolism in Pacific Asia with direct oral anticoagulants. Thrombosis Research, 2015, 136, 196-207.	1.7	5
139	Direct Oral Anticoagulants and Their Use in Treatment and Secondary Prevention of Acute Symptomatic Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 209-221.	1.7	5
140	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. TH Open, 2018, 02, e1-e7.	1.4	5
141	Netâ€clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. Journal of Thrombosis and Haemostasis, 2019, 17, 2089-2098.	3.8	5
142	ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. European Journal of Internal Medicine, 2020, 82, 48-55.	2.2	5
143	ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3Âmonths. Thrombosis Research, 2020, 196, 297-304.	1.7	5
144	Impact of Surgery Type and Co-Morbidities on Venous Thromboembolism prophylaxis Practices in Patients Undergoing Major Surgical Procedures in Acute Care Hospitals Worldwide: A Subanalysis of Data from the ENDORSE Survey. Blood, 2008, 112, 171-171.	1.4	5

#	Article	IF	Citations
145	Pharmacological Prevention of Venous Thromboembolism in Medical Patients at Risk. American Journal of Cardiovascular Drugs, 2005, 5, 409-415.	2.2	4
146	Excellence, quality and limitations of the <scp>NICE</scp> venous thromboembolism score tool: how can it be improved?. British Journal of Haematology, 2014, 167, 702-704.	2.5	4
147	Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK. Journal of Market Access & Health Policy, 2018, 6, 1495974.	1.5	4
148	Magnitude of Venous Thromboembolism Risk in US Hospitals: Impact of Evolving National Guidelines for Prevention of Venous Thromboembolism. American Journal of Medicine, 2019, 132, 588-595.	1.5	4
149	Double trouble for cancer patients. European Heart Journal, 2021, 42, 2308-2310.	2.2	4
150	Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism. Blood, 2012, 120, LBA-1-LBA-1.	1.4	4
151	Time in Therapeutic Range (TTR) and Relative Efficacy and Safety of Treatment with Apixaban or Enoxaparin/Warfarin for Acute Symptomatic Venous Thromboembolism: An Analysis of the Amplify Trial Data. Blood, 2014, 124, 1543-1543.	1.4	4
152	Is there a role for low-dose DOACs as prophylaxis?. Hematology American Society of Hematology Education Program, 2019, 2019, 187-193.	2.5	4
153	Betrixaban in Acutely Ill Medical Patients. New England Journal of Medicine, 2016, 375, e50.	27.0	3
154	Recommendations for Research Assessing Outcomes for Patients With Anticoagulant-Related Intracerebral Bleeds. Stroke, 2021, 52, 1520-1526.	2.0	3
155	Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer. Current Medical Research and Opinion, 2021, 37, 1467-1482.	1.9	3
156	The MAGELLAN Study: An Analysis of Outcomes Utilizing D-Dimer. Blood, 2011, 118, 542-542.	1.4	3
157	The Unmet Need for Extended Thromboprophylaxis in Acutely Ill Medical Patients: The Findings of IMPROVE, ENDORSE and EXCLAIM.. Blood, 2008, 112, 1981-1981.	1.4	3
158	Cancerâ€Associated ThrOmboSIs â€“ Patientâ€Reported OutcoMes With RivarOxaban (COSIMO) â€“ Baseline characteristics and clinical outcomes. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12604.	2.3	3
159	Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis. Journal of Medical Economics, 2019, 22, 1063-1072.	2.1	2
160	Assessment of the burden of disease for patients with peripheral artery disease undergoing revascularization in England. Vascular Medicine, 2022, 27, 440-449.	1.5	2
161	NOACs for thromboprophylaxis in medical patients. Best Practice and Research in Clinical Haematology, 2013, 26, 183-190.	1.7	1
162	Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. TH Open, 2019, 03, e103-e108.	1.4	1

#	Article	IF	Citations
163	Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study. Haematologica, 2019, 104, e474-e477.	3.5	1
164	Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 259-267.	1.4	1
165	Venous Thromboembolism Risk and Prophylaxis Practices in Surgical Patients with Active Cancer: Findings from the Global ENDORSE Survey.. Blood, 2008, 112, 984-984.	1.4	1
166	Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial. Thrombosis Research, 2022, 211, 63-69.	1.7	1
167	Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence?. Thrombosis and Haemostasis, 2009, 101, 422-7.	3.4	1
168	Impact of Patient Characteristics on Treatment Outcomes in Symptomatic Venous Thromboembolism: Results of HOKUSAI-VTE Randomized Trial Analysis. TH Open, 2020, 04, e245-e254.	1.4	0
169	Fatal Pulmonary Embolism and Cancer - a Post Mortem Study.. Blood, 2004, 104, 2593-2593.	1.4	0
170	Venous Thromboembolic Risk and Suboptimal Prophylaxis in the US Acute Hospital Care Setting: Findings from the ENDORSE Study.. Blood, 2007, 110, 1858-1858.	1.4	0
171	Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica, 2021, , .	3.5	0